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Abstract
Tissue factor pathway inhibitor (TFPI) plays a vitally important role in the blood coagulation pathway. Recent studies
indicated that TFPI induces apoptosis in vascular smooth-muscle cells (VSMCs) in animals. The present study in-
vestigated whether the TFPI gene could also induce apoptosis in human vascular smooth-muscle cells (hVSMCs).
Such cells were isolated from human umbilical arteries and subsequently transfected with pIRES-TFPI plasmid (2
g/mL). MTT assaying and cell counting were applied to measure cell viability and proliferation, RT-PCR was utilized
to analyze TFPI gene expression in the cells. Apoptosis was analyzed by fluorescence activated cell sorting (FACS).
Several key proteins involved in apoptosis were examined through Western blotting. It was shown that TFPI gene
transfer led to its increased cellular expression, with a subsequent reduction in hVSMC proliferation. Further investi-
gation demonstrated that TFPI gene expression resulted in lesser amounts of procaspase-3, procaspase-8 and
procascase-9, and an increased release of mitochondrial cytochrome c (cyt-c) into cytoplasm, thereby implying the
involvement of both extrinsic and intrinsic pathways in TFPI gene-induced apoptosis in hVSMCs.
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Introduction
Restenosis, a major complication leading to recurrent
acute coronary diseases and even death (Douglas, 2007),
occurs in 30%-40% of the patients following percutaneous
transluminal coronary angioplasty (PTCA). To date, the
underlying mechanisms are not yet completely understood,
even though several etiological factors have already been
identified, these including the proliferation and migration
of VSMCs, platelet adherence and aggregation, thrombus
formation, the infiltration of inflammatory cells, as well as
vascular remodeling (Ferns and Avades, 2000; Kaiura et
al., 2000; Santin et al., 2004).
Thetissuefactor(TF)isakeyinitiatorofthecoagula-
tion cascade (DelGiudice and White, 2009). It also partici-
pates in other cellular processes including migration and
proliferation of VSMCs (Ducasse et al., 2003). It has been
shown to mediate a prolonged prothrombotic state after
balloon angioplasty, by generating active serine proteases
of the coagulation cascade, these including factor VIIa
(VIIa), factor Xa, and thrombin (Ducasse et al., 2003).
These proteases promote the development of restenosis by
both thrombotic and non-thrombotic mechanisms, exerting
mitogenicandchemotacticeffectsonVSMCsandbyelicit-
ing a proinflammatory response (Ko et al., 1996; Senden et
al., 1998). Hence, the possibility of blocking TF activity
couldleadtoareductioninthrombosis,localinflammation,
and the proliferation and migration of VSMCs, and, conse-
quently, intimal hyperplasia in injured blood vessels.
The tissue factor pathway inhibitor (TFPI), a Kunitz-
type protease inhibitor, exerts feedback inhibition on the
TF/VIIa-complexinanXa-dependentmanner(Brozeetal.,
1990). It has been attracting increasing research effort as a
potential agent for curing restenosis, since it was found to
attenuatethrombusformation(Nishidaetal.,1999),reduce
local inflammatory responses induced by injury to blood
vessels, and suppress the proliferation and migration of
VSMCs (Kamikubo et al., 1997). Research, based on ani-
mal models, has amply confirmed that TFPI, in the form of
either recombinant protein or gene, reduce restenosis in-
duced by blood vessel injury (Hamuro et al., 1998; Hem-
brough et al., 2001; Sato et al., 1997, 1999; Yin et al.,
2002). Since VSMCs proliferation and migration plays a
central role in the progression of neointimal hyperplasia, it
is of particular interest to understand the mechanism
through which TFPIs modulate the former of the two.
Apoptosis induction is one of the major strategies for
reducing cell proliferation. Recent investigation using ani-
mal models has revealed that adenovirus-mediated TFPI
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Research Articlegene transfer induced apoptosis in VSMCs through the in-
trinsicpathway(Fuetal.,2008),addingmoreevidencetoa
deeper understanding of the mechanisms underlying its
anti-proliferative behavior. Even so, little is known regard-
ing the impact of the TFPI gene on hVSMCs.
The current study was designed to investigate
whether TFPI could induce also apoptosis in hVSMCs, as
well as the underlying mechanisms involved. We could
show that TFPI over-expression in human VSMCs induced
cellular apoptosis through both intrinsic and extrinsic
apoptotic pathways.
Materials and Methods
Isolation and identification of VSMCs
hVSMCs were isolated from human umbilical artery
according to the method described by Li et al. (2003).
Briefly,3-5cmsectionsofarteriesisolatedfromthehuman
umbilical cord were perfused with a physiological saline
solution to remove the remaining internal blood. This was
done by means of a 20 mL syringe connected to a needle.
After cutting open and gently scraping off the intima, the
blood vessels were sectioned into even smaller pieces of
2-3 mm
3, for culture in 25 cm
2 flasks, with DMEM supple-
mented with 10% fetal-calf serum (FBS) and 10% human
AB serum. Culture itself was by incubation in a humidified
5% CO2 incubator at 37 °C. The medium was refreshed ev-
ery 3 days until the cells reached about 90% confluence.
Purification of hVSMCs was carried out by differential at-
tachment, the cells of passage 3 being used for further in-
vestigation. The isolated hVSMCs were identified by
immunocytochemical staining, using monoclonal antibod-
ies against smooth muscle actin-, according to manufac-
turer's instructions, with a non-specific serum as antibody
control.
Construction of the TFPI encoding plasmid
In order to construct a recombinant plasmid express-
ing TFPI in eukaryotic cells, TFPI cDNA, a generous gift
from Professor George J. Broze Jr. at Washington Univer-




Detection of TFPI expression in VSMCs by RT-PCR
hVSMCs were seeded into 25 cm
2 flasks and incu-
batedovernightat37°Cinahumidified5%CO2incubator.
Thereafter, the cells were divided into 3 groups
(8 flasks/group) and treated with pIRES-TFPI plasmid
(2 g/mL), pIRES 1-neo plasmid (2 g/mL) and fresh me-
dium, respectively, using lipofectamine as transfection re-
agent according to manufacturer's instructions. Total RNA
was extracted with Trizol reagent 3 days after transfection,
and subsequently amplified by RT-PCR with TFPI specific
primers(5'-GGAAGAAGATCCTGGAATATGTCGAGG
-3', and 5'-CTTGGTTGATTGCGGAGTCAGGGAG-3').
GAPDH was amplified as internal control, using the fol-
lowing primers: 5'-ACCACAGTCCATGCCATCACT-3'
and 5'-TCCACACCCTGTTGCTGTA-3'. The amplified
DNA was analyzed through electrophoresis followed by
optical density scanning using a GDS8000 Gel Documen-
tation and Analysis System (Cambridge, UK).
Testing of cell viability by MTT assay
hVSMCs were seeded into a 96-well plate and incu-
batedovernightat37°Cinahumidified5%CO2incubator.
The cells were divided into 3 groups (8 wells/group) and
treated with pIRES-TFPI plasmid (2 g/mL), pIRES 1-neo
plasmid (2 g/mL) and fresh medium, respectively, using
lipofectamine as transfection reagent according to manu-
facturer's instructions. Cell viability was measured 3, 5 and
7 days after DNA transfection by MTT assay as described
previously(Mosmann,1983).Thetestwasrepeatedtwice.
Measurement of cell proliferation
hVSMCs were seeded into a 48-well plate and incu-
bated at 37 °C in a humidified 5% CO2 incubator. Cells
were divided into three groups, and treated with pIRES-
TFPI plasmid (2 g/mL), pIRES 1-neo plasmid (2 g/mL)
and fresh medium, respectively, using lipofectamine as
transfection reagent, according to manufacturer's instruc-
tions. The cells were counted using a cytometer from 2 to
7 days after DNA transfection. The experiment was re-
peated twice.
Flow-cytometry for cell apoptosis analysis
hVSMCs were seeded into 25 cm
2 flasks and incu-
batedovernightat37°Cinahumidified5%CO2incubator.
The cells, divided into three groups, were treated with
pIRES-TFPIplasmid(2g/mL),pIRES1-neoplasmidand
fresh medium, respectively, using lipofectamine as trans-
fection reagent, according to manufacturer's instructions.
Harvesting was done 5 and 7 days after transfection. Cells
were first washed with PBS and counted, and then sus-
pended in a 1x binding buffer at a density of1x1 0
6
cells/mL. After transfer toa5m Lculture tube, 100 Lo f
the cell suspension (1 x 10
5 cells) was transferred toa5m L
culture tube and then gently mixed with 5 L of FITC-
Annexin V and 10 L of PI solution. After a 15 min's incu-
bation in the dark at RT, 400 L of 1x binding buffer was
added to each tube, followed by FACS analysis (NJ, USA).
The experiment was repeated twice.
Western blotting
Western blotting was performed to verify the amount
of the proteins involved in apoptosis. In brief, 5 days after
DNA transfection, the cells were harvested, washed with
PBS,andresuspendedincoldlysisbuffercontainingPMSF
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ice for 30 min and centrifuged at 12,000 g for 10 min at
4 °C. The amount of protein was determined using a Brad-
ford protein-assay kit. Aliquots of the cell lysates contain-
ing 50 g of proteins were mixed with SDS-sample buffers
and subjected to electrophoresis on 10% PAGE gels fol-
lowed by routine Western blotting analysis using antibod-
ies against procaspase-8, procaspase-9, procaspase-3, cyt-
c, and -actin (Santa Cruz,USA). The experiment was re-
peated three times and the results were presented as mean
values of the three tests.
Statistical analysis
Statistical analysis was performed using one way
ANOVA (one-way analysis of variance) followed by Bon-
ferroni t-tests for comparisons with the control group. The
valueswerepresentedasmeansSDofeighttests,andsta-
tistical significance was determined at p < 0.05.
Results
TFPI gene transfer led to elevated TFPI expression
in hVSMCs
TFPI mRNA levels in hVSMCs were determined by
RT-PCR, with simultaneously amplified GAPDH, as inter-
nal control. As shown in Figure 1A, a DNA fragment of
around230bpswasamplifiedbyTFPIspecificprimersand
a DNA fragment of around 500 bps by GAPDH specific
primers. Figure 1B shows that the TFPI/ GAPDH ratio in
cells treated with pIRES-TFPI (1.50) was significantly
higherthaninthosetreatedwithpIRES1-neo(0.70)ornor-
mal ones (0.60). The fact of there being no significant dif-
ference in treatment between the pIRES 1-neo treated cells
and normal cells indicates that TFPI gene transfer did, in
fact, result in higher expression of TFPI.
Suppressed cell viability and proliferation as a result
of TFPI gene transfer
Both MTT assay and cell counting demonstrated that
pIRES-TFPI gene transfer resulted in decreased cell viabil-
ity and proliferation, in a time dependent manner, com-
pared with pIRES 1-neo plasmid treatment, thereby infer-
ring the inhibitory effect of the TFPI gene on VSMCs
proliferation (Figure 2).
TFPI gene induced cell apoptosis in hVSMCs
The results obtained demonstrated that TFPI gene
transferstartedtorevealitsinhibitoryeffectonVSMCpro-
liferation from the 5
th day after DNA transfection (Figure
2). Thus, the 5
th and 7
th days post-transfection were chosen
for observing the impact of TFPI gene transfer on cellular
apoptosis. We found that the TFPI gene induced signifi-
cantly higher cellular apoptosis in comparison to experi-
mental controls (Figure 3). To further explore the
underlying mechanisms, certain key proteins involved in
apoptosis were analyzed through Western blotting, show-
ing that TFPI gene transfer led to decreased expression of
procaspase-3, procaspase-8 and procascase-9, and in-
creasedreleaseofcyt-cintothecytoplasmincomparisonto
the control groups (Figure 4).
Discussion
Both the abnormal proliferation and migration of
VSMCs contribute significantly to restenosis progression
after cardiovascular intervention such as PTCA, which
leads to high long-term failure rates of bypass surgery and
angioplasty in the treatment of cardiovascular diseases.
Therefore, the development of molecular strategies that ef-
fectivelyblocksuchpathogeniccellularprocesseshasbeen
the focus of much research and many clinical trials over the
past two decades (Kiernan et al., 2008, 2009).
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Figure 1 - Analysis of RT-PCR amplification of TFPI by agarose gel electrophoresis. (A) M: DNA maker; 1: TFPI amplification in the non-transfection
group; 2: TFPI amplification in pIRES 1-neo group; 3: TFPI amplification in the pIRES-TFPI group; 4: GAPDH amplification in the non-transfection
group; 5: GAPDH amplification in the pIRES 1-neo group; 6: GAPDH amplification in the pIRES-TFPI group. (B) TFPI mRNA levels standardized by
GAPDH.
*p < 0.05 as compared to the pIRES 1-neo or non-transfection group (n = 8).VSMCs usually comprise two phenotypes, namely
contractile and synthetic. The contractile phenotype cells
are spindle-shaped with low frequency of proliferation,
whereasthesyntheticphenotypecellsarerhomboid-shaped
showing a high degree of protein synthesis, proliferation
and migratory activity. It is generally agreed that contrac-
tile differentiated VSMCs are the typical phenotype of the
vascularwallundermostnormal,physiologicalconditions,
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Figure 2 - Cell viability measured by MTT. (A) Cell proliferation measured by cell counting. B
*p < 0.05 as compared with the pIRES 1-neo group (n =
16);
p < 0.05 as compared with the non-transfection group (n = 16).
Figure 3 - Cell apoptosis analysis at the 5
th (A) and 7
th (B) days after gene transfection.
*p < 0.05 in comparison to the pIRES 1-neo group or the
non-transfection group (n = 8).
Figure 4 - Western blot analysis for procaspase-8, procaspase-9, procaspase-3, and cyt-c. (A) Representative data of Western blotting for pIRES-TFPI
treatedgroup(a),pIRES1-neotreatedgroup(b)andnon-transfectiongroup(c);(B)proteinlevelsstandardizedby-actin.
*p<0.05ascomparedwiththe
pIRES 1-neo group (n = 3).whereas synthetic dedifferentiated VSMCs only exist dur-
ing developmental and pathological processes. In response
tovariousstimuliincludingvascularinjury,VSMCsswitch
from the quiescent contractile phenotype to the synthetic
one,proliferateinmedia,andmigratefromthemediatothe
intima, where they undergo further proliferation leading to
neointimal hyperplasia. Reduction of neointimal hyperpla-
sia could be achieved either by regulating the cell cycle
(cytostatic strategy), or by inducing cell-death, such as
apoptosis (cytotoxic strategy).
Apoptosis normally occurs during development and
aging,asahomeostaticmechanismtomaintaincellpopula-
tions in tissues. It also operates as a defense mechanism
against cell-damage induced by diseases or noxious agents
(Norbury and Hickson, 2001). The highly complex and so-
phisticatedapoptosismechanismsinvolveacascadeofmo-
lecular events. It is generally agreed that there are two
major apoptotic pathways, the extrinsic or death receptor
pathway and the intrinsic or mitochondrial pathway. Re-
cent evidence demonstrates that the two pathways are
linked and converge on the execution pathway (Igney and
Krammer, 2002). The extrinsic pathway involves the bind-
ing of ligands to their corresponding death receptors, fol-
lowed by a series of molecular events leading to
auto-catalytic activation of procaspase-8 (Kischkel et al.,
1995). In the intrinsic pathway, apoptosis is triggered by a
varied array of intracellular signals that act directly on tar-
gets within the cell. All these signals induce changes in the
inner mitochondrial membrane, thereby leading to opening
of the mitochondrial permeability transition pore, loss of
mitochondrial transmembrane potential, and the release of
pro-apoptotic proteins, such as cyt-c, from intermembrane
space into the cytosol (Saelens et al., 2004). Cyt-c binds to
andactivatesApaf-1,aswellasprocaspase-9,therebylead-
ing to caspase-9 activation (Chinnaiyan, 1999; Hill et al.,
2004). Both pathways end at the execution phase. Cas-
pase-3, considered to be the most important of the execu-
tioner caspases, is activated by any one of the initiator
caspases including caspase-8 and caspase-9.
As demonstrated in the current study, TFPI gene
transfer could suppress the proliferation of neonatal
VSMCs from human umbilical artery that share character-
istics similar to those of synthetic VSMCs observed in
restenosis lesions (Fujita et al., 1993). This is in line with a
previous report showing TFPI gene-induced apoptosis in
rat VSMCs by (Fu et al., 2008). Nevertheless, the current
study showed that TFPI gene transfer reduced the expres-
sion of caspase 3, caspase 8, and caspase 9 and induced the
release of cyt-c into the cytosol. This implies the involve-
ment of both extrinsic and intrinsic pathways in TFPI
gene-induced cellular apoptosis, contrary to that observed
inrats,whereonlytheintrinsicpathwaywasaffected(Fuet
al., 2008). The mechanisms underlying the difference in
impact of the TFPI gene on apoptotic pathways needs to be
further elucidated.
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